WALTHAM, Mass.--(BUSINESS WIRE)--BG Medicine, Inc. today announced that it has entered into an agreement with Abbott Laboratories (NYSE: ABT) to extend its current development and commercialization collaboration to include the development of a galectin-3 test for Abbott Point of Care’s i-STAT® System. Galectin-3 is a novel biomarker that may play a role in detecting the development and progression of heart failure.
